Abstract
Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have